Atlas Trials

A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines

Clinical trial NCT04281095 · COMPLETED

Trial details

NCT number
NCT04281095
Sponsor
ATGC Co., Ltd.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Glabellar Frown Lines
Start date
2019-11-01
Primary completion
2020-04-30
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.